SeaX Ventures bets US$1.65M on Skribe Medical’s AI heart patch for cancer patients
Surviving cancer can come with a cruel footnote. Some of the therapies that shrink tumours can quietly weaken the heart. Clinicians call it cancer therapy-related cardiac dysfunction (CTRCD), and catching it early usually means repeated echocardiograms, the heart ultrasounds that demand separate appointments, trained sonographers and, too often, a pause in treatment while oncologists wait […] The…
Skribe Medical, a U.S. medtech startup, has secured a $1.65 million investment from SeaX Ventures to develop an AI-powered heart patch for cancer patients. The Aurora System, consisting of a multi-sensor adhesive patch and AI technology, estimates left ventricular ejection fraction (LVEF), a crucial indicator for oncologists monitoring heart function during cancer treatment.
Skribe's NOECHO clinical study, involving over 800 patients across 10 U.S. sites and one in Southeast Asia, compares the patch's readings with traditional echocardiography. While the FDA's READI-Home Innovation Challenge selection provides Skribe with early engagement and feedback, it does not guarantee regulatory approval. The company's co-founder and CEO, Ryan Neely, emphasizes reducing patient burden by integrating heart function checks into regular oncology visits, with home monitoring as the longer-term goal.
Written by urgent.news from e27's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
